A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 145, Issue 2, 2017, Pages 291-297

  Rader, Janet S ^a   Sill, Michael W ^b   Beumer, Jan H ^c,d   Lankes, Heather A ^b   Benbrook, Doris Mangiaracina ⁿ   Garcia, Francisco ^e   Trimble, Connie ^f   Tate Thigpen, J ^g   Lieberman, Richard ^h   Zuna, Rosemary E ^d   Leath, Charles A ⁱ   Spirtos, Nick M ^j   Byron, John ^k   Thaker, Premal H ^l   Lele, Shashikant ^b   Alberts, David ^m  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j Women's Cancer Center of Nevada   (United States)

^k First Health Moore Regional Hospital   (United States)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF ARIZONA   (United States)

ⁿ UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

Celecoxib; Cervix; Chemoprevention; CIN 3; COX 2; VEGF

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; VASCULOTROPIN; CYCLOOXYGENASE 2 INHIBITOR; PTGS2 PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANEMIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CERVICAL INTRAEPITHELIAL NEOPLASIA 3; COLPOSCOPY; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; NEUROLOGICAL COMPLICATION; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TELEPATHOLOGY; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; YOUNG ADULT; ADOLESCENT; BLOOD; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIAL; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; ADULT; BIOMARKERS, TUMOR; CELECOXIB; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 85014744834     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.02.040     Document Type: Article

References (37)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136:5 (2015), E359–E386.
2. [2] Jin, G., LanLan, Z., Li, C., Dan, Z., Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Arch. Gynecol. Obstet. 289 (2014), 85–99.
3. [3] Meyskens, F.L., Surwit, E., Moon, T.E., Childers, J.M., Davis, J.R., Dorr, R.T., et al. Enhancement of regression of CIN II with topically applied all-trans-retinoic acid: a randomized trial. J. Natl. Cancer Inst. 86 (1994), 539–543.
4. [4] Romney, S.L., Ho, G.Y., Palan, P.R., Basu, J., Kadish, A.S., Klein, S., et al. Effects of B-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol. Oncol. 65 (1997), 483–492.
5. [5] Vlastos, A.T., West, L.A., Atkinson, E.N., Boiko, I., Malpica, A., Hong, W.K., et al. Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin. Cancer Res. 11 (2005), 390–396.
6. [6] Bell, M.C., Crowley-Nowick, P., Bradlow, H.L., Sepkovic, D.W., Schmidt-Grimminger, D., Howell, P., et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol. Oncol. 78 (2000), 123–129.
7. [7] Van Pachterbeke, C., Bucella, D., Rozenberg, S., Manigart, Y., Gilles, C., Larsimont, D., et al. Topical treatment of CIN 2 + by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol. Oncol. 115 (2009), 69–74.
8. [8] Grimm, C., Polterauer, S., Natter, C., Rahhal, J., Hefler, L., Tempfer, C.B., et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet. Gynecol. 120 (2012), 152–159.
9. [9] Farley, J.H., Truong, V., Goo, E., Uyehara, C., Belnap, C., Larsen, W.I., A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia. Gynecol. Oncol. 103 (2006), 425–430.
10. [10] Ferrandina, G., Lauriola, L., Distefano, M.G., Zannoni, G.F., Gessi, M., Legge, F., et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J. Clin. Oncol. 20 (2002), 973–981.
11. [11] Kulkarni, S., Rader, J.S., Zhang, F., Liapis, H., Koki, A.T., Masferrer, J.L., et al. Cyclooxygenas-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7 (2001), 429–434.
12. [12] Wang, D., Dubois, R.N., Eicosanoids and cancer. Nat. Rev. Cancer 10 (2010), 181–193.
13. [13] Bertagnolli, M.M., Eagle, C.J., Zauber, A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355 (2006), 873–884.
14. [14] Elmets, C.A., Viner, J.L., Pentland, A.P., Cantrell, W., Lin, H.Y., Bailey, H., et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J. Natl. Cancer Inst. 102 (2010), 1835–1844.
15. [15] Derosa, L., Galli, L., Orlandi, P., Fioravanti, A., Di Desidero, T., Fontana, A., et al. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer 120 (2014), 3923–3931.
16. [16] Wei, D., Wang, L., He, Y., Xiong, H.Q., Abbruzzese, J.L., Xie, K., Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64 (2004), 2030–2038.
17. [17] Xu, X., Jiang, M., Zhang, Y., Bi, Y., Han, M., Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor. Mol. Med. Rep. 11 (2015), 289–294.
18. [18] Rosas, C., Sinning, M., Ferreira, A., Fuenzalida, M., Lemus, D., Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy. Biol. Res., 47, 2014, 27.
19. [19] Sui, W., Zhang, Y., Wang, Z., Wang, Z., Jia, Q., Wu, L., et al. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H(2)(2) murine hepatocarcinoma model. Oncol. Rep. 31 (2014), 2252–2260.
20. [20] Halamka, M., Cvek, J., Kubes, J., Zavadova, E., Kominek, P., Horacek, J., et al. Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer. Oral Oncol. 47 (2011), 763–767.
21. [21] Zhu, Y.M., Azahri, N.S., Yu, D.C., Woll, P.J., Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells. BMC Cancer, 8, 2008, 218.
22. [22] Mao, J.T., Roth, M.D., Fishbein, M.C., Aberle, D.R., Zhang, Z.F., Rao, J.Y., et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev. Res. (Phila.) 4 (2011), 984–993.
23. [23] Gius, D., Funk, M.C., Chuang, E.Y., Feng, S., Huettner, P.C., Nguyen, L., et al. Profiling Microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res. 67 (2007), 7113–7123.
24. [24] Smith-McCune, K., Zhu, Y.H., Hanahan, D., Arbeit, J., Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res. 57 (1997), 1294–1300.
25. [25] Smith-McCune, K.K., Weidner, N., Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 54 (1994), 800–804.
26. [26] Hammes, L.S., Tekmal, R.R., Naud, P., Edelweiss, M.I., Kirma, N., Valente, P.T., et al. Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol. Oncol. 110 (2008), 445–451.
27. [27] Obermair, A., Bancher-Todesca, D., Bilgi, S., Kaider, A., Kohlberger, P., Mullauer-Ertl, S., et al. Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 89 (1997), 1212–1217.
28. [28] Hefler, L.A., Grimm, C., Speiser, P., Sliutz, G., Reinthaller, A., The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II–III A phase II trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 125 (2006), 251–254.
29. [29] Grabosch, S.M., Shariff, O.M., Wulff, J.L., Helm, C.W., Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia. Cochrane Database Syst. Rev., 4, 2014, CD004121.
30. [30] Alberts, D.S., Potter, J.D., Martinez, M.E., Hess, L.M., Stopeck, A., Lance, P., What happened to the coxibs on the way to the cardiologist?. Cancer Epidemiol. Biomark. Prev. 14 (2005), 555–556.
31. [31] Brenner, S.S., Herrlinger, C., Dilger, K., Murdter, T.E., Hofmann, U., Marx, C., et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin. Pharmacokinet. 42 (2003), 283–292.
32. [32] Frank, D.H., Roe, D.J., Chow, H.H., Guillen, J.M., Choquette, K., Gracie, D., et al. Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial. Cancer Epidemiol. Biomark. Prev. 13 (2004), 299–303.
33. [33] Sauter, E.R., Qin, W., Hewett, J.E., Ruhlen, R.L., Flynn, J.T., Rottinghaus, G., et al. Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women. BMC Cancer, 8, 2008, 49.
34. [34] Kim, E.S., Hong, W.K., Lee, J.J., Mao, L., Morice, R.C., Liu, D.D., et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev. Res. (Phila.) 3 (2010), 148–159.
35. [35] Steinbach, G., Lynch, P.M., Phillips, R.K., Wallace, M.H., Hawk, E., Gordon, G.B., et al. The effect of Celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000), 1946–1952.
36. [36] Wirth, L.J., Krane, J.F., Li, Y., Othus, M., Moran, A.E., Dorfman, D.M., et al. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev. Res. (Phila.) 1 (2008), 339–348.
37. [37] Darragh, T.M., Colgan, T.J., Thomas Cox, J., Heller, D.S., Henry, M.R., Luff, R.D., et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int. J. Gynecol. Pathol. 32 (2013), 76–115.